Ladenburg lowered the firm’s price target on Checkpoint Therapeutics to $69 from $96 and keeps a Buy rating on the shares, citing dilution associated with recent capital raises for the lower target. Cosibelimab’s BLA being accepted for metastatic and locally advanced cutaneous squamous cell carcinoma is "a significant milestone," the analyst tells investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CKPT:
- Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Checkpoint Therapeutics prices $6.1M registered direct offering at $3.60
- Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
- Checkpoint Therapeutics price target lowered to $32 from $41 at Lake Street
- Checkpoint Therapeutics announces FDA filing acceptance of BLA for cosibelimab